Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mevidalen (LY3154207) sleep latency study in healthy subjects
NCT02603861Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2015
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mevidalen in Lewy body dementia (LBD), Parkinson's disease dementia (PDD), narcolepsy and 1 more (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to Sleep Onset. Started Nov 2015; status: completed.
02
Drugs
mevidalen
03
Conditions
Lewy body dementia (LBD)Parkinson's disease dementia (PDD)narcolepsyhypersomnolence disorder
Beyond the preview
Go deeper on NCT02603861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603861.